Obinutuzumab

Obinutuzumab ^?

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD20
Clinical data
Legal status	℞-only (US)
Pharmacokinetic data
Half-life	28.4 days
Identifiers
CAS number	949142-50-1 N
ATC code	L01XC15
UNII	O43472U9X8 Y
KEGG	D09321 Y
Chemical data
Formula	C6512H10060N1712O2020S44
Mol. mass	146.1 kDa
N (what is this?)  (verify)

Obinutuzumab (called afutuzumab until 2009^[1]) is a humanized monoclonal antibody, originated by Glycart Biotechnology AG and developed by Biogen Idec, Chugai Pharmaceutical Co., and Hoffmann-La Roche Inc. for the treatment of lymphoma.^[2] It acts as an immunomodulator.^[3][4]

Obinutuzumab targets CD20 and kills B cells.^[2]

Obinutuzumab was approved under the tradename Gazyva by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients. Patients treated with Gazyva had median survival of 23 months before death or disease progression, compared with 11.1 months for patients on chemotherapy alone.^[5]

References

1. ↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
2. ↑ 2.0 2.1 Robak, T (2009). "GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies". Current opinion in investigational drugs (London, England : 2000) 10 (6): 588–96. PMID 19513948. 
3. ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Afutuzumab, American Medical Association.
4. ↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
5. ↑ Associated Press, published in the New York Times. November 1, 2013 F.D.A. Clears New Cancer-Fighting Drug From Roche